Cellectis to Present Data on Genome Engineering for Adoptive Immunotherapy at the American Society of Clinical Oncology Annual Meeting
Business Wire - Wed May 13, 5:00PM CDT
Regulatory News:
CLLS: 32.25 (+0.86)
Cellectis S.A. to Present Data on its Allogeneic CAR T Cell Programs at American Society of Gene & Cell Therapy Annual Meeting
Business Wire - Thu May 07, 5:00PM CDT
Regulatory News:
CLLS: 32.25 (+0.86)
Cellectis Plant Sciences Becomes Calyxt
Business Wire - Mon May 04, 5:05PM CDT
Cellectis plant sciences, Inc., a Minnesota-based Company focusing on developing healthier food products, announced today that it has changed its corporate name to Calyxt, Inc. The company will use this new name as of today.
Cellectis S.A. Announces Calyxt is New Name for Its Plant Sciences Subsidiary
Business Wire - Mon May 04, 5:00PM CDT
Regulatory News:
CLLS: 32.25 (+0.86)
Cellectis Plant Sciences, Inc. Locks Early CRISPR Intellectual Property Uses in Plants
Business Wire - Wed Apr 15, 5:02PM CDT
Regulatory News:
Cellectis Plant Sciences, Inc. Publishes a Study Demonstrating Reduced Acrylamide in Fried Potatoes
Business Wire - Tue Apr 14, 5:14PM CDT
Regulatory News:
Cellectis Announces Presentations at Upcoming Conferences
Business Wire - Thu Apr 09, 5:24PM CDT
Regulatory News:
CLLS: 32.25 (+0.86)
Cellectis Opens Labs and Offices in Manhattan, New York
Business Wire - Wed Apr 08, 5:17PM CDT
Regulatory News:
CLLS: 32.25 (+0.86)
Citi Appointed Depositary Bank for Cellectis' ADR Programme
Business Wire - Wed Apr 08, 6:44AM CDT
Citi, acting through Citibank N.A., has been appointed by Cellectis S.A. ("Cellectis"
C: 54.24 (-0.36)
Cellectis Prices Initial Public Offering of American Depositary Shares
Business Wire - Tue Mar 24, 8:29PM CDT
Regulatory News:
Medigene AG: Addressing The CAR-T Market Pain Points
Decision Analytics - Seeking Alpha - Wed Mar 18, 11:51AM CDT
I have written about the market opportunity for adoptive cancer immunotherapy before when my interest was piqued by the incredible appreciation of a number of early-stage CAR-T therapy companies (a form of adoptive immunotherapy). Companies such as...
MDVN: 122.90 (-0.47), JNJ: 102.30 (+0.47), ZIOP: 9.17 (-0.17), BLCM: 23.02 (-1.37), KITE: 50.02 (-2.24), JUNO: 43.37 (-1.52), NVS: 103.75 (-0.15)
Cellectis: Finding Value In A Crowded CAR-T Space
Bay Area Biotech - at Seeking Alpha - Tue Mar 10, 8:51PM CDT
Chimeric Antigen Receptor (CAR)-engineered T-cells are an exciting, emerging new space in cancer therapy. At recent American Society of Hematology (ASH) annual meetings, the CAR presentations were met with the most fanfare, attention,...
BLUE: 154.42 (-2.98), ZIOP: 9.17 (-0.17), PFE: 33.99 (+0.05), XON: 40.08 (-0.90), AMGN: 162.36 (+0.38), GSK: 44.77 (-0.22), IMUC: 0.48 (+0.01), CELG: 115.53 (+0.45), JNJ: 102.30 (+0.47), BLCM: 23.02 (-1.37), KITE: 50.02 (-2.24), JUNO: 43.37 (-1.52), NVS: 103.75 (-0.15)
Cellectis SA Shareholders General Meeting of February 16, 2015
Business Wire - Tue Feb 17, 12:26PM CST
Regulatory News:
Not For The Faint Of CAR-T: The CAR-T Landscape In Early 2015
EP Vantage - Seeking Alpha - Fri Feb 06, 1:26PM CST
This is an extract from a longer report. If you followed last year's explosion of enthusiasm in CAR therapies you might have assumed that this was a super-novel approach that had just burst onto the scientific stage. In fact work on the synthetic...
BLUE: 154.42 (-2.98), CLRB: 2.74 (+0.08), BLCM: 23.02 (-1.37), KITE: 50.02 (-2.24), JUNO: 43.37 (-1.52), NVS: 103.75 (-0.15)
CAR-T Vs ErbB3 Market Opportunity Comparison
Decision Analytics - Seeking Alpha - Wed Jan 21, 12:32PM CST
CAR-T therapy, also known as "Adoptive Immunotherapy", has been the result of significant investor excitement recently. One look at the stock charts for JUNO and KITE is illustrative of this optimism. While this enthusiasm may be warranted,...
MACK: 12.66 (+0.34), BLUE: 154.42 (-2.98), ZIOP: 9.17 (-0.17), BLCM: 23.02 (-1.37), KITE: 50.02 (-2.24), AVEO: 1.19 (-0.04), JUNO: 43.37 (-1.52), GSK: 44.77 (-0.22), REGN: 489.01 (-2.42), NVS: 103.75 (-0.15)
Kite Pharma/Amgen: A Strong Combination
Henry Wolfe - at Seeking Alpha - Thu Jan 15, 12:19PM CST
ZIOP: 9.17 (-0.17), BLCM: 23.02 (-1.37), KITE: 50.02 (-2.24), AMGN: 162.36 (+0.38), JUNO: 43.37 (-1.52)
Cellectis and Ohio State University, Through the Ohio State Innovation Foundation, Enter Into Licensing Agreement for Chimeric Antigen Receptor Technology Targeting Multiple Myeloma
Business Wire - Tue Jan 13, 12:30AM CST
Regulatory News:
Cellectis Plans to Conduct Registered Initial Public Offering in the U.S.
Business Wire - Thu Jan 08, 12:17PM CST
Regulatory News:
Cellectis Announces the Issuance by the USPTO of a Patent Covering a Seminal Nuclease-Based "gene editing" Method
Business Wire - Tue Jan 06, 11:30AM CST
Regulatory News:
Cellectis Is Late To The CAR-T Cell Race, But Could Finish First
Intrepid Investor - at Seeking Alpha - Fri Jan 02, 3:21PM CST
BLUE: 154.42 (-2.98), BLCM: 23.02 (-1.37), KITE: 50.02 (-2.24), JUNO: 43.37 (-1.52), GSK: 44.77 (-0.22), NVS: 103.75 (-0.15), CELG: 115.53 (+0.45)